Global Blood Resources

Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapeutics for underserved patient communities, with a primary focus on sickle cell disease (SCD). The company's flagship product, Oxbryta (voxelotor), is a first-in-class oral therapy that inhibits hemoglobin polymerization, the root cause of red blood cell sickling. GBT's pipeline includes inclacumab, a monoclonal antibody targeting P-selectin to reduce vaso-occlusive crises, and next-generation hemoglobin S polymerization inhibitors. In 2022, GBT was acquired by Pfizer for approximately $5.4 billion to bolster its hematology portfolio and expand its reach in rare blood disorders.